AxoSim

Our AxoSim page will no longer be active. Be sure to follow the 28bio LinkedIn page: https://xmrrwallet.com/cmx.plnkd.in/eFECzkAC We look forward to continuing this journey with you. 🧠 #MPS #Organoids #Neuroscience #Neurotechnology #DrugDevelopment

Breaking news: AxoSim is now 28bio. As 28bio, we’re unveiling the Nexon™ neurotechnology platform, powered by engineered human brains. The Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today’s neurological health crisis by improving the ability to predict which therapies will work in humans. It also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer’s disease. Learn more here: https://xmrrwallet.com/cmx.plnkd.in/e5SpyD6F #neurotechnology #organoids #drugdevelopment #neuroscience #biotech #AI

🇧🇪 Next stop: Belgium! AxoSim will be at the MPS World Summit! As regulatory momentum builds, we’re looking forward to meaningful conversations—and sharing what we’ve been working on. 📣Booth #117 🔬Posters -      Peripheral nerve microphysiological system for screening neuropathy of small molecule and PROTAC chemotherapeutics. -      Development of an AI-based target discovery identification model for anticonvulsant drug discovery. -      Improving the stability and reproducibility of clinical neurotoxicity predictions from a high-throughout compatible neural organoid platform. 💡Need dedicated time to speak with an expert? Schedule a meeting today. https://xmrrwallet.com/cmx.plnkd.in/eBB_JYDj Excited to connect over breakthroughs (and maybe a few waffles 🧇). See you in Belgium! #MPSWorldSummit #Neurotechnology #Organoids #BrainScience

We are thrilled to be at the Applied Pharmaceutical Toxicology (#APT) conference this week where David Gallegos, PhD, Senior Scientist at Takeda will be presenting on their work with AxoSim brain organoids for #neurotoxicity. If you will be onsite, be sure to reach out to our team who can help with any questions you have. https://xmrrwallet.com/cmx.phubs.li/Q03mbTt10

We’re living through a turning point in drug discovery & development. The FDA is phasing out animal models. The NIH is shifting funding priorities to support organoids and organ-on-a-chip technologies. For those of us who’ve championed human-relevant science, this is more than policy—it’s validation. It’s hope. It’s the future arriving. To mark this moment and help others take part in this movement, we’re now offering: Buy 1, Get 1 Free on brain organoids for neurotoxicity safety testing. Because progress is better when we share it. Get started today: https://xmrrwallet.com/cmx.phubs.li/Q03kCXRz0 #Organoids DrugDevelopment #NAMs #LifeSciences #Biotech #Neurotoxicity

It has been an exciting couple of weeks for everyone involved with #NAMs and #Organoid technology. Be sure to read the recent article by Rowan Walrath at C&EN: https://xmrrwallet.com/cmx.phubs.li/Q03kxTjz0 “The human brain is incredibly complex. It’s incredibly intricate. Animals just don’t have a brain that’s representative, quite frankly, of anything close to a human brain,” says Alif Saleh, CEO of AxoSim, which develops brain organoids. “The idea that a mouse brain or a rat brain or any other animal brain can predict how a human brain would react to a particular drug—it's not credible. Yet up until this point, this has been the only solution that pharma has had available to them.” AxoSim essentially makes miniature brains by growing human neurological cells in hundreds upon hundreds of small plastic wells. Those cells naturally form a 3D organoid. In a number of days—Saleh doesn’t say how many—they form a lab-grown brain representative of the brain of a teenager. They keep growing and eventually become a decent mirror of a 35-year-old.

In a landmark decision, the FDA has begun the process of phasing out mandatory animal testing — a move that signals a shift decades in the making. We believe this moment is more than a policy change — it’s a recognition of scientific progress bringing us closer to using human biology to solve human health challenges. To celebrate this historic step forward, we’re offering a limited-time opportunity to new customers ready to shift to brain organoids. Buy 2, Get 1 Free — MicroBrain™ Plates Offer Details - Offer only available to new AxoSim customers - Access to 96- and 384-well MicroBrain™ formats - A 1-hour onboarding session to support seamless adoption - Order deadline: June 15, 2025 - Delivery deadline: June 30, 2025 - While supplies last We’re proud of how far we’ve come — and even more excited for the work ahead. Get started today: https://xmrrwallet.com/cmx.phubs.li/Q03jxFPT0 #FDA #NAMs #Organoids #DrugDevelopment

The FDA’s decision to begin phasing out animal testing marks a monumental milestone in the shift toward a human-first approach in science and drug development. This is more than a regulatory change—it’s a powerful signal that the future of therapeutics lies in more predictive, human-relevant models. As we take a moment to celebrate this milestone and applaud Commissioner Martin A. Makary for his leadership, we also want to recognize the incredible work of our peers across the microphysiological systems field. Your dedication to developing new approach methodologies (NAMs), advocating for their adoption, and pushing the boundaries of innovation has brought us all to this pivotal moment and we are proud to stand with you. At AxoSim, we know this shift brings exciting opportunities—and important questions. As the industry begins further implementation of new technologies and approaches, we’re here to help navigate the change. Now is the time for continued collaboration, courage, and commitment. Together, we can turn this bold vision—leveraging human biology therapeutic development—into reality. FDA Roadmap to Reducing Animal Testing in Preclinical Studies: https://xmrrwallet.com/cmx.phubs.li/Q03hf26C0 #FDAPolicy #NeurotoxicityTesting #NAMs #MPS #MicrophysiologicalSystems #Organoids #DrugDevelopment #Biotech

Join AxoSim at SOT 2025 – Booth #1310! We’re excited to connect at the 64th Annual Society of Toxicology (SOT) Meeting & ToxExpo in Orlando, March 16-20, 2025! Stop by booth #1310 to explore how our human-relevant 3D neuro models offer deeper insights into neurological diseases and disorders. Let’s discuss how we can help de-risk your pipeline with predictive, high-throughput solutions. Don’t miss our poster presentations on March 19, 1:45–4:15 PM: - Non-invasive cytotoxicity assessment for safety & efficacy screening (Poster 4632/J468) - 3D Nerve-on-a-Chip vs. 2D neuronal assays for ADC toxicity screening (Poster 4626/J462) - Enhancing reproducibility of clinical neurotoxicity predictions (Poster 4633/J469) Schedule a meeting in advance to secure time with our experts! https://xmrrwallet.com/cmx.phubs.li/Q038_d8Q0 #SOT2025 #ToxExpo #Neurotoxicity #3DNeuralModels #DrugDiscovery #iPSC

New research is shedding light on distinct functional phenotypes in human models of rare neurodevelopmental disorders. Using advanced microphysiological systems (MPS), our study demonstrates how clinically related conditions exhibit unique electrophysiological and morphological signatures—offering deeper insights into disease mechanisms and potential therapeutic strategies. Key Findings - Rare neurodevelopmental disorders display differentiated functional phenotypes in human neuronal models. - Electrophysiology & imaging-based analyses reveal disease-specific biomarkers. - Microphysiological systems provide a translational bridge for drug discovery. Understanding these functional distinctions is crucial for developing targeted therapies and improving patient outcomes. View poster: https://xmrrwallet.com/cmx.phubs.li/Q038G0J30 #Neuroscience #NeurodevelopmentalDisorders #RareDiseases #DrugDiscovery #Innovation